Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Pluristem’s Ongoing Phase III CLI trial has been selected for accelerated approval pathways in both the U.S. and EuropeFast Track Designation allows for expedited review of drugs to treat serious...
-
HAIFA, Israel, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the company...
-
Company steps up its clinical platform with pipeline of three late-stage clinical indicationsAll late-stage programs are supported and funded by 3rd parties with over $19 million in non-dilutive...
-
With funding now in place Pluristem plans to launch a multinational Phase III in U.S. and EuropeTotal of $16.7 Million (15 million Euro) in non-dilutive funding have been awarded from the Horizon...
-
The DOD studies seek to test the effectiveness of PLX-R18 as a novel medical countermeasure for Acute Radiation Syndrome (ARS) prior to and within 24 hours of exposure to high levels of radiationThe...
-
HAIFA, Israel, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has been...
-
Findings pave the way to potentially use PLX-R18 to support hematological recovery following radiotherapy or chemotherapyData focuses on 12 additional NHPs that were exposed to lower radiation levels ...
-
Austria’s regulatory health agency clears CLI study and joins the U.S., U.K., and Germany in conducting the 250-patient Phase III trial HAIFA, Israel, July 10, 2017 (GLOBE NEWSWIRE) -- Pluristem...
-
HAIFA, Israel, June 29, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that new data...
-
HAIFA, Israel, May 22, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial results...